Indication intelligence, analysis and sector perception

Prime Medicine (PRME) a gene editing company has raised $175 million selling 1.4 million shares in the middle of its $17-$19 price range in its IPO

October 20, 2022 2:10pm

PRME notched a valuation of about $1.8 billion in its Nasdaq debut on Thursday, after its shares opened nearly 12% above their offer price; but, traded at $15.88 down -$1.12 or -6.59% started trading at $18.97 apiece, compared to its initial public offering price of $17 each.

The offering is expected to close on October 24, 2022, subject to the satisfaction of customary closing conditions.

A new class of differentiated one-time curative genetic therapies founded by Harvard biochemist David Liu, is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90% of known disease-causing genetic mutations across many organs and cell types from the same man who was one of those inventing CRISPR

It's also one of the most successful U.S. IPOs in recent memory, as Prime for a $1.7 billion fully diluted market value.

Prime had raised $315 million in VC funding, most recently in April 2021 at a $1.2 billion valuation, from such firms as GV (14.6% pre-IPO stake), Arch Venture Partners (13.4%), F-Prime Capital Partners (13.4%) and Newpath Partners (5.7%). It will list on the Nasdaq under ticker symbol It "PRME."

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price fewer underwriting discounts and commissions.

J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.